A Phase 2 interventional study of Deucravacitinib and Placebo in Alopecia Areata, sponsored by Bristol-Myers Squibb. Terminated at 28 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.
Among the 98 studies in Alopecia Areata with a site in United States, this one is the 21st largest by enrollment of the 84 interventional ones that give a count, is one of 7 that started in 2022, is one of 42 in phase 2, and was the 67th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Japan and 1 more country
Ages 6–17
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18–60
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Almirall, S.A. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 48 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 46 across the 84 interventional studies, 2,300 across the 14 observational. Of the 60 that completed or were terminated, 42 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 98 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 1 study filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
10 of the studies in Alopecia Areata with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
| NCT06826196Aldena TherapeuticsA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | 2026-11 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 98 studies in Alopecia Areata with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Drug: Deucravacitinib · Other: Placebo
Drug: Deucravacitinib · Other: Placebo
Drug: Deucravacitinib · Other: Placebo
Specified dose on specified days
Also known as: BMS-986165
Placebo was administered.
Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period
The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp: back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by it's respective weighting factor (percentage surface area of the scalp in that area; back region \[24%\], top region \[40%\], left region \[18%\] and, right region \[18%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata.
Time frame: Baseline (Day 1) and Week 24
Number of Participants With Treatment Emergent Adverse Events in Placebo-Controlled Period
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included herpes zoster, malignancy, opportunistic infection or tuberculosis infection.
Time frame: From first dose (Day 1) and up to 30 days after last dose for all participants (up to approximately 28 weeks)
Number of Participants With Treatment Emergent Adverse Events in Active Treatment Period
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included Herpes zoster, malignancy, opportunities infection or tuberculosis infection.
Time frame: From first dose (Day 1) of Week 25 and up to 30 days after last dose for all participants (up to approximately 28 weeks)
Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in Placebo-Controlled Period
Blood samples were collected for assessment of laboratory test results. All abnormalities were graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
Time frame: From first dose (Day 1) through Week 24
Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in in Active Treatment Period
Blood samples were collected for assessment of laboratory test results. All abnormalities are graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
Time frame: From Week 25 to Week 52
Number of Participants With Marked Electrocardiogram Abnormalities in Placebo-Controlled Period
A 12-lead ECG was performed after the participant remained supine for at least 5 minutes prior to the ECG. The ECG results read by the principal study investigator or a qualified and delegated designee as per local requirements
Time frame: First dose (Day 1) to Week 24
Number of Participants With Marked Electrocardiogram Abnormalities in Active Treatment Period
A 12-lead ECG should be performed after the participant has remained supine for at least 5 minutes prior to the ECG. The ECG results will be read by the principal study investigator or a qualified and delegated designee as per local requirements
Time frame: Week 25 to Week 52
Number of Participants With Abnormalities in Marked Vital Signs in Placebo-Controlled Period
Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant has been resting quietly for at least 5 minutes.
Time frame: First dose (Day 1) to Week 24
Number of Participants With Abnormalities in Marked Vital Signs in Active Treatment Period
Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant had been resting quietly for at least 5 minutes.
Time frame: Week 25 to Week 52
Number of Participants With Abnormalities in Targeted Physical Examination Parameters in Placebo-Controlled Period
Participants were assessed for abnormalities in targeted physical parameters.
Time frame: First dose (Day 1) to Week 24
Number of Participants With Abnormalities in Targeted Physical Examination Parameters in Active Treatment Parameters
Participants were assessed for abnormalities in targeted physical parameters.
Time frame: Week 25 to Week 52
Percentage of Participants Achieving a ≥ 50% Reduction in Severity of Alopecia Tool (SALT) Score (SALT50 Response) From Baseline at Week 24
The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. SALT50 response indicates at least a 50% improvement from baseline in the SALT score at a particular time point, indicating 50% hair regrowth.
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants Achieving a Severity of Alopecia Tool (SALT) Score ≤20 at Week 24
The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. percentage of participants achieving an absolute SALT score ≤ 20, indicates ≤ 20% scalp hair loss.
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants Achieving an Alopecia Areata Investigator Global Assessment (AA-IGA) Score of 0 or 1 at Week 24 With at Least a 2-Point Change From Baseline
The AA-IGA utilizes a 5-points scale, in which the investigator assesses scalp hair loss based on the SALT assessment. The AA-IGA measures alopecia areata severity at a single point in time(without taking into account the baseline disease condition).The participant's scalp hair loss, as it look at the time of evaluation is scored as none (0) (0% scalp hair loss), limited (1) (1%-20% scalp hair loss), moderate (2) (21%-49% scalp hair loss), severe (3) (50%-94% scalp hair loss), or very severe (4)(95%-100 % scalp hair loss).
Time frame: Baseline (Day 1) and week 24
Study was terminated due to change in business objectives.
| Milestone | Deucravacitinib 6 mg QD | Deucravacitinib 6 mg BID | Placebo | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|---|
| Started | 32 | 31 | 31 | 0 | 0 |
| Completed | 32 | 26 | 31 | 0 | 0 |
| Not completed | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant request to discontinue study treatment | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 | 0 |
| Milestone | Deucravacitinib 6 mg QD | Deucravacitinib 6 mg BID | Placebo | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|---|
| Started | 32 | 26 | 0 | 16 | 15 |
| Completed | 8 | 5 | 0 | 5 | 3 |
| Not completed | 24 | 21 | 0 | 11 | 12 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 3 | 1 |
| Withdrew: Participant request to discontinue study treatment | 1 | 3 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 19 | 12 | 0 | 6 | 9 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 1 | 0 |
The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp: back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by it's respective weighting factor (percentage surface area of the scalp in that area; back region \[24%\], top region \[40%\], left region \[18%\] and, right region \[18%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata.
| Score on a Scale | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period | -5.809 ± 13.3892 | 1.027 ± 14.7258 | -7.302 ± 17.8732 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included herpes zoster, malignancy, opportunistic infection or tuberculosis infection.
| Participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| Treatment Emergent Adverse Events | 25 | 28 | 20 |
| Serious Treatment Emergent Adverse Events | 1 | 1 | 0 |
| Treatment Emergent Adverse Events Leading to Discontinuation of Study | 1 | 3 | 0 |
| TEAE of Interest-Herpes Zoster | 1 | 0 | 0 |
| TEAE of Interest-Malignancy-Bowen's Disease) | 0 | 1 | 0 |
| TEAE of Interest-Malignancy-Nodular lymphocyte predominant Hodgkin Lymphoma | 0 | 1 | 0 |
| TEAE of Interest - Opportunistic Infections | 0 | 0 | 0 |
| TEAE of Interest - Tuberculosis Infection | 0 | 0 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included Herpes zoster, malignancy, opportunities infection or tuberculosis infection.
| Participants | Active Treatment Period: Deucravacitinib 6 mg QD | Active Treatment Period: Deucravacitinib 6 mg BID | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|
| Treatment Emergent Adverse Events | 21 | 17 | 13 | 14 |
| Serious Treatment Emergent Adverse Events | 0 | 1 | 0 | 0 |
| Treatment Emergent Adverse Events Leading to Discontinuation of Study | 1 | 0 | 1 | 0 |
| TEAE of Interest-Herpes Zoster | 0 | 0 | 0 | 0 |
| TEAE of Interest-Malignancy-Bowen's Disease | 0 | 0 | 0 | 0 |
| TEAE of Interest-Malignancy-Nodular lymphocyte predominant Hodgkin Lymphoma | 0 | 0 | 0 | 0 |
| TEAE of Interest - Opportunistic Infections | 0 | 0 | 0 | 0 |
| TEAE of Interest - Tuberculosis Infection | 0 | 0 | 0 | 0 |
Blood samples were collected for assessment of laboratory test results. All abnormalities were graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
| Participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| HEMOGLOBIN, LOW | 0 | 0 | 0 |
| PLATELET COUNT, LOW | 0 | 0 | 0 |
| LEUKOCYTES, LOW | 0 | 0 | 0 |
| ALANINE AMINOTRANSFERASE (ALT), HIGH | 0 | 0 | 0 |
| ALKALINE PHOSPHATASE (ALP), HIGH | 0 | 0 | 0 |
| ASPARTATE AMINOTRANSFERASE (AST), HIGH | 0 | 0 | 0 |
| BILIRUBIN, TOTAL, HIGH | 0 | 0 | 0 |
| CREATININE, ENZYMATIC, HIGH | 0 | 0 | 0 |
| ALBUMIN, LOW | 0 | 0 | 0 |
| CALCIUM, LOW | 0 | 0 | 0 |
| CALCIUM, HIGH | 0 | 0 | 0 |
| CHOLESTEROL, TOTAL (TC), HIGH | 0 | 0 | 0 |
| CREATINE KINASE (CK), HIGH | 0 | 1 | 2 |
| GLUCOSE, LOW | 0 | 0 | 0 |
| POTASSIUM, LOW | 0 | 0 | 0 |
| POTASSIUM, HIGH | 0 | 0 | 0 |
| SODIUM, LOW | 0 | 0 | 0 |
| SODIUM, HIGH | 0 | 0 | 0 |
| TRIGLYCERIDES, HIGH | 0 | 0 | 0 |
| GLUCOSE FASTING, LOW | 0 | 0 | 0 |
Blood samples were collected for assessment of laboratory test results. All abnormalities are graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
| Participants | Active Treatment Period: Deucravacitinib 6 mg QD | Active Treatment Period: Deucravacitinib 6 mg BID | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|
| HEMOGLOBIN, LOW | 0 | 0 | 0 | 0 |
| PLATELET COUNT, LOW | 0 | 0 | 0 | 0 |
| LEUKOCYTES, LOW | 0 | 0 | 0 | 0 |
| ALANINE AMINOTRANSFERASE (ALT), HIGH | 0 | 0 | 0 | 0 |
| ALKALINE PHOSPHATASE (ALP), HIGH | 0 | 0 | 0 | 0 |
| ASPARTATE AMINOTRANSFERASE (AST), HIGH | 0 | 0 | 0 | 0 |
| BILIRUBIN, TOTAL, HIGH | 0 | 0 | 0 | 0 |
| CREATININE, ENZYMATIC, HIGH | 0 | 0 | 0 | 0 |
| ALBUMIN, LOW | 0 | 0 | 0 | 0 |
| CALCIUM, LOW | 0 | 0 | 0 | 0 |
| CALCIUM, HIGH | 0 | 0 | 0 | 0 |
| CHOLESTEROL, TOTAL (TC), HIGH | 0 | 0 | 0 | 0 |
| CREATINE KINASE (CK), HIGH | 0 | 0 | 0 | 0 |
| GLUCOSE, LOW | 0 | 0 | 0 | 0 |
| POTASSIUM, LOW | 0 | 0 | 0 | 0 |
| POTASSIUM, HIGH | 0 | 0 | 0 | 0 |
| SODIUM, LOW | 0 | 0 | 0 | 0 |
| SODIUM, HIGH | 0 | 0 | 0 | 0 |
| TRIGLYCERIDES, HIGH | 0 | 0 | 0 | 0 |
| GLUCOSE FASTING, LOW | 0 | 0 | 0 | 0 |
A 12-lead ECG was performed after the participant remained supine for at least 5 minutes prior to the ECG. The ECG results read by the principal study investigator or a qualified and delegated designee as per local requirements
| Participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| QTCF 450 -< 480 MILLISECONDS (MSEC) | 0 | 2 | 1 |
| QTCF 480 -< 500 MSEC | 0 | 0 | 0 |
| QTCF >= 500 MSEC | 0 | 0 | 0 |
| QTCF 30 < CHANGE FROM BASELINE <= 60 MSEC | 0 | 1 | 0 |
| QTCF CHANGE FROM BASELINE > 60 MSEC | 0 | 0 | 0 |
| PR INTERVAL >= 200 MSEC | 2 | 0 | 1 |
| QRS INTERVAL >= 120 MSEC | 0 | 0 | 1 |
A 12-lead ECG should be performed after the participant has remained supine for at least 5 minutes prior to the ECG. The ECG results will be read by the principal study investigator or a qualified and delegated designee as per local requirements
| Participants | Active Treatment Period: Deucravacitinib 6 mg QD | Active Treatment Period: Deucravacitinib 6 mg BID | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|
| QTCF 450 -< 480 MILLISECONDS (MSEC) | 0 | 0 | 0 | 0 |
| QTCF 480 -< 500 MSEC | 0 | 0 | 0 | 0 |
| QTCF >= 500 MSEC | 0 | 0 | 0 | 0 |
| QTCF 30 < CHANGE FROM BASELINE <= 60 MSEC | 1 | 1 | 1 | 1 |
| QTCF CHANGE FROM BASELINE > 60 MSEC | 0 | 0 | 0 | 0 |
| PR INTERVAL >= 200 MSEC | 1 | 0 | 1 | 1 |
| QRS INTERVAL >= 120 MSEC | 1 | 0 | 1 | 0 |
Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant has been resting quietly for at least 5 minutes.
| Participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| HEART RATE > 100 BPM AND CHANGE FROM BASELINE > 30 BPM | 0 | 1 | 0 |
| HEART RATE < 55 BPM AND CHANGE FROM BASELINE < -15 BPM | 1 | 0 | 0 |
| SBP >140 MM HG AND CHANGE FROM BASELINE > 20 MM HG | 1 | 4 | 1 |
| SBP <90 MM HG AND CHANGE FROM BASELINE < -20 MM HG | 0 | 0 | 1 |
| DBP >90 MM HG AND CHANGE FROM BASELINE > 10 MM HG | 3 | 0 | 1 |
| DBP <55 MM HG AND CHANGE FROM BASELINE < -10 MM HG | 0 | 0 | 1 |
Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant had been resting quietly for at least 5 minutes.
| Participants | Active Treatment Period: Deucravacitinib 6 mg QD | Active Treatment Period: Deucravacitinib 6 mg BID | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|
| HEART RATE > 100 BPM AND CHANGE FROM BASELINE > 30 BPM | 0 | 0 | 0 | 1 |
| HEART RATE < 55 BPM AND CHANGE FROM BASELINE < -15 BPM | 1 | 1 | 0 | 0 |
| SBP >140 MM HG AND CHANGE FROM BASELINE > 20 MM HG | 1 | 1 | 0 | 1 |
| SBP <90 MM HG AND CHANGE FROM BASELINE < -20 MM HG | 0 | 0 | 0 | 0 |
| DBP >90 MM HG AND CHANGE FROM BASELINE > 10 MM HG | 0 | 1 | 0 | 3 |
| DBP <55 MM HG AND CHANGE FROM BASELINE < -10 MM HG | 1 | 0 | 1 | 0 |
The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. SALT50 response indicates at least a 50% improvement from baseline in the SALT score at a particular time point, indicating 50% hair regrowth.
| Percentage of participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving a ≥ 50% Reduction in Severity of Alopecia Tool (SALT) Score (SALT50 Response) From Baseline at Week 24 | 3.1 | 0 | 6.5 |
The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. percentage of participants achieving an absolute SALT score ≤ 20, indicates ≤ 20% scalp hair loss.
| Percentage of participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving a Severity of Alopecia Tool (SALT) Score ≤20 at Week 24 | 3.1 | 0 | 0 |
The AA-IGA utilizes a 5-points scale, in which the investigator assesses scalp hair loss based on the SALT assessment. The AA-IGA measures alopecia areata severity at a single point in time(without taking into account the baseline disease condition).The participant's scalp hair loss, as it look at the time of evaluation is scored as none (0) (0% scalp hair loss), limited (1) (1%-20% scalp hair loss), moderate (2) (21%-49% scalp hair loss), severe (3) (50%-94% scalp hair loss), or very severe (4)(95%-100 % scalp hair loss).
| Percentage of participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving an Alopecia Areata Investigator Global Assessment (AA-IGA) Score of 0 or 1 at Week 24 With at Least a 2-Point Change From Baseline | 3.1 | 0 | 0 |
Participants were assessed for abnormalities in targeted physical parameters.
| Participants | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo |
|---|---|---|---|
| Abdomen | 0 | 0 | 1 |
| Extremities | 0 | 1 | 1 |
| General Appearance | 1 | 1 | 0 |
| Genitourinary | 1 | 0 | 0 |
| Head, Eyes, Ears, Nose, Throat | 3 | 6 | 2 |
| Lymph Nodes | 0 | 0 | 0 |
| Mouth | 3 | 0 | 0 |
| Musculoskeletal | 1 | 1 | 0 |
| Neck | 0 | 0 | 0 |
| Neurological | 2 | 0 | 1 |
| Psychiatric | 1 | 0 | 1 |
| Respiratory | 0 | 1 | 1 |
| Skin | 9 | 14 | 6 |
| Other | 1 | 1 | 0 |
Participants were assessed for abnormalities in targeted physical parameters.
| Participants | Active Treatment Period: Deucravacitinib 6 mg QD | Active Treatment Period: Deucravacitinib 6 mg BID | Active Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active Treatment Period: Placebo Followed bDeucravacitinib 6 mg BID |
|---|---|---|---|---|
| Abdomen | 0 | 3 | 0 | 0 |
| Extremities | 0 | 1 | 0 | 0 |
| General Appearance | 0 | 0 | 0 | 0 |
| Genitourinary | 1 | 1 | 0 | 0 |
| Head, Eyes, Ears, Nose, Throat | 0 | 5 | 2 | 2 |
| Lymph Nodes | 0 | 1 | 0 | 0 |
| Mouth | 2 | 1 | 1 | 2 |
| Musculoskeletal | 1 | 2 | 1 | 0 |
| Neck | 0 | 1 | 0 | 0 |
| Neurological | 0 | 0 | 0 | 0 |
| Other | 2 | 2 | 0 | 4 |
| Psychiatric | 0 | 0 | 0 | 1 |
| Respiratory | 1 | 3 | 0 | 2 |
| Skin | 8 | 6 | 5 | 8 |
Collected over All cause mortality was collected from Week 0 to Week 52. Serious AEs were collected from informed consent form signing (Week -4) and up to 30 days after last dose for all participants (up to approximately 32 weeks and 28 weeks in Placebo-controlled and Active Treatment Period respectively). Non Serious AEs were collected from first dose (Day 1) and up to 30 days after last dose (up to approximately 28 weeks for each Placebo-controlled and Active Treatment Period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Controlled: Deucravacitinib 6 mg QD | 0/32 (0%) | 1/32 (3.1%) | 24/32 (75%) |
| Placebo-Controlled: Deucravacitinib 6 mg BID | 0/31 (0%) | 1/31 (3.2%) | 26/31 (83.9%) |
| Placebo | 0/31 (0%) | 0/31 (0%) | 16/31 (51.6%) |
| Active-Treatment Period: Deucravacitinib 6 mg QD | 0/32 (0%) | 0/32 (0%) | 15/32 (46.9%) |
| Active-Treatment Period: Deucravacitinib 6 mg BID | 0/26 (0%) | 1/26 (3.8%) | 14/26 (53.8%) |
| Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | 0/16 (0%) | 0/16 (0%) | 13/16 (81.3%) |
| Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| Event | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo | Active-Treatment Period: Deucravacitinib 6 mg QD | Active-Treatment Period: Deucravacitinib 6 mg BID | Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|---|---|---|
| Ligament sprainInjury, poisoning and procedural complications | 0/32 | 0/31 | 0/31 | 0/32 | 1/26 | 0/16 | 0/15 |
| Nodular lymphocyte predominant Hodgkin LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 1/31 | 0/31 | 0/32 | 0/26 | 0/16 | 0/15 |
| Viral upper respiratory tract infectionInfections and infestations | 1/32 | 0/31 | 0/31 | 0/32 | 0/26 | 0/16 | 0/15 |
| Event | Placebo-Controlled: Deucravacitinib 6 mg QD | Placebo-Controlled: Deucravacitinib 6 mg BID | Placebo | Active-Treatment Period: Deucravacitinib 6 mg QD | Active-Treatment Period: Deucravacitinib 6 mg BID | Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD | Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/32 | 4/31 | 4/31 | 4/32 | 5/26 | 4/16 | 4/15 |
| AcneSkin and subcutaneous tissue disorders | 5/32 | 4/31 | 3/31 | 0/32 | 0/26 | 3/16 | 4/15 |
| NasopharyngitisInfections and infestations | 5/32 | 8/31 | 0/31 | 2/32 | 6/26 | 2/16 | 1/15 |
| FolliculitisInfections and infestations | 5/32 | 6/31 | 1/31 | 0/32 | 0/26 | 0/16 | 1/15 |
| Aphthous ulcerGastrointestinal disorders | 3/32 | 4/31 | 1/31 | 0/32 | 2/26 | 1/16 | 2/15 |
| Food poisoningGastrointestinal disorders | 0/32 | 1/31 | 0/31 | 0/32 | 0/26 | 0/16 | 2/15 |
| COVID-19Infections and infestations | 3/32 | 1/31 | 0/31 | 1/32 | 1/26 | 0/16 | 2/15 |
| DiarrhoeaGastrointestinal disorders | 1/32 | 4/31 | 0/31 | 0/32 | 0/26 | 0/16 | 0/15 |
| EczemaSkin and subcutaneous tissue disorders | 1/32 | 1/31 | 0/31 | 0/32 | 0/26 | 2/16 | 1/15 |
| Urinary tract infectionInfections and infestations | 1/32 | 3/31 | 0/31 | 2/32 | 1/26 | 0/16 | 0/15 |
| Age, Continuous(years) | Deucravacitinib 6 mg QD | Deucravacitinib 6 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 36.1 ± 13.37 | 43.4 ± 13.81 | 38.9 ± 14.40 | 39.4 ± 14.04 |
| Sex: Female, Male(Participants) | Deucravacitinib 6 mg QD | Deucravacitinib 6 mg BID | Placebo | Total |
|---|---|---|---|---|
| Female | 22 | 22 | 20 | 64 |
| Male | 10 | 9 | 11 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Deucravacitinib 6 mg QD | Deucravacitinib 6 mg BID | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 0 | 4 |
| Not Hispanic or Latino | 31 | 28 | 31 | 90 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Deucravacitinib 6 mg QD | Deucravacitinib 6 mg BID | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 8 | 6 | 10 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 2 | 7 |
| White | 22 | 20 | 19 | 61 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from Nov 2022 to primary completion in Jan 2024, 13 months.
Results were first posted in Feb 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib